# Oncologist Treatment Plan

## Analysis Output

# æ²»ç–—æ–¹æ¡ˆåˆ¶å®šæŠ¥å‘Š

## 1. æ‰§è¡Œæ‘˜è¦ (Executive Summary)

æ‚£è€…ä¸º 70 å²ç”·æ€§ï¼ŒIV æœŸä¹™çŠ¶ç»“è‚ è…ºç™Œï¼ˆKRAS G12C+, MSS, TMB-H, ATM èƒšç³»çªå˜ï¼‰ï¼Œç›®å‰å¤„äºäº”çº¿æ²»ç–—é˜¶æ®µï¼ˆæ°Ÿæ³½é›·èµ› + è¥¿å¦¥æ˜”å•æŠ—ï¼‰ã€‚
**æ ¸å¿ƒç­–ç•¥**ï¼š
1.  **å½“å‰æ²»ç–—**ï¼š**æ°Ÿæ³½é›·èµ› + è¥¿å¦¥æ˜”å•æŠ—** æ˜¯åŸºäº KRAS G12C çªå˜çš„æœ€ä½³å¾ªè¯é€‰æ‹©ï¼Œä½†é‰´äºæ‚£è€… eGFR çº¦ 39 mL/min åŠæ—¢å¾€ TKI è‚¾æŸä¼¤å²ï¼Œéœ€æé«˜å¼ºåº¦çš„è‚¾åŠŸèƒ½ç›‘æµ‹ã€‚
2.  **åç»­å‚¨å¤‡**ï¼šè‹¥å½“å‰æ–¹æ¡ˆè¿›å±•ï¼Œé¦–é€‰ **TAS-102 + è´ä¼ç å•æŠ—**ï¼ˆæ ‡å‡†æ²»ç–—ï¼‰ï¼Œæˆ–åŸºäº ATM çªå˜å°è¯• **PARP æŠ‘åˆ¶å‰‚**ï¼ˆä¸´åºŠè¯•éªŒ/è¶…é€‚åº”ç—‡ï¼‰ã€‚
3.  **å®‰å…¨è­¦ç¤º**ï¼šæ‚£è€…è‚¾åŠŸèƒ½å¤„äº CKD 3b æœŸï¼ˆeGFR < 40 mL/minï¼‰ï¼Œä¸”åˆå¹¶å¿ƒè¡€ç®¡ç–¾ç—…ï¼Œéœ€ä¸¥æ ¼è§„é¿è‚¾æ¯’æ€§è¯ç‰©å¹¶ç®¡ç†è¯ç‰©ç›¸äº’ä½œç”¨ã€‚

---

## 2. æ²»ç–—è·¯çº¿å›¾ (Treatment Roadmap)

### ğŸ”´ å½“å‰æ–¹æ¡ˆ (Current Regimen) - ç»´æŒä¸ç›‘æµ‹
**æ–¹æ¡ˆåç§°**: æ°Ÿæ³½é›·èµ› (Fulzerasib/IBI351) + è¥¿å¦¥æ˜”å•æŠ— (Cetuximab)
**è¯æ®ç­‰çº§**: B (åŸºäºåŒç±»è¯ç‰© Sotorasib/Adagrasib çš„ III æœŸæ•°æ®åŠ IBI351 æ—©æœŸæ•°æ®)
**æ²»ç–—å®šä½**: äº”çº¿æŒ½æ•‘æ²»ç–— (é’ˆå¯¹ KRAS G12C)

*   **åˆç†æ€§**:
    *   KRAS G12C æŠ‘åˆ¶å‰‚è”åˆ EGFR å•æŠ—æ˜¯è¯¥äºšå‹çš„æ ‡å‡†æ²»ç–—ç­–ç•¥ã€‚CodeBreaK 300 ç ”ç©¶æ˜¾ç¤ºï¼ŒSotorasib + Panitumumab è¾ƒæ ‡å‡†æ²»ç–—æ˜¾è‘—å»¶é•¿ PFS [[1]](#ref-pmid-37870968)ã€‚
    *   æ°Ÿæ³½é›·èµ›æ˜¯ä¸­å›½åŸç ”è¯ç‰©ï¼Œæ—©æœŸæ•°æ®æ˜¾ç¤ºåœ¨ CRC ä¸­å…·æœ‰è‰¯å¥½æ´»æ€§ã€‚

*   **é¢„æœŸç–—æ•ˆ**:
    *   ORR: ~30-40%
    *   mPFS: ~5-6 ä¸ªæœˆ

*   **âš ï¸ å…³é”®å®‰å…¨ç®¡ç† (è‚¾åŠŸèƒ½ä¼˜å…ˆ)**:
    *   **ç°çŠ¶**: æ‚£è€… eGFR ä¼°ç®—çº¦ä¸º **39 mL/min** (Cockcroft-Gault å…¬å¼)ï¼Œå±ä¸­é‡åº¦è‚¾åŠŸèƒ½ä¸å…¨ã€‚
    *   **é£é™©**: æ—¢å¾€å‘‹å–¹æ›¿å°¼å¯¼è‡´æ€¥æ€§è‚¾æŸä¼¤ã€‚è™½ç„¶ KRAS G12C æŠ‘åˆ¶å‰‚è‚¾æ¯’æ€§ä½äº VEGFR TKIï¼Œä½† Adagrasib è¯´æ˜ä¹¦æç¤ºæœ‰è‚¾å—æŸé£é™© [[4]](#ref-fda-adagrasib label)ã€‚
    *   **è¡ŒåŠ¨**:
        *   **å‰ 2 ä¸ªæœˆ**: æ¯ 2 å‘¨ç›‘æµ‹è¡€è‚Œé…ã€å°¿è›‹ç™½ã€‚
        *   **é¿å…è„±æ°´**: ç¡®ä¿æ¯æ—¥é¥®æ°´é‡ï¼Œé¢„é˜²è…¹æ³»å¯¼è‡´çš„è¡€å®¹é‡ä¸è¶³ã€‚

---

### ğŸ”µ ä¼˜é€‰åçº¿æ–¹æ¡ˆ (Option 2) - æ ‡å‡†æ²»ç–—
**æ–¹æ¡ˆåç§°**: TAS-102 (æ›²æ°Ÿå°¿è‹·æ›¿åŒ¹å˜§å•¶) + è´ä¼ç å•æŠ—
**è¯æ®ç­‰çº§**: A (NCCN Category 1)
**æ²»ç–—å®šä½**: å…­çº¿/åçº¿æ ‡å‡†æ²»ç–—

*   **åˆç†æ€§**:
    *   SUNLIGHT ç ”ç©¶è¯å®ï¼ŒTAS-102 è”åˆè´ä¼ç å•æŠ—è¾ƒ TAS-102 å•è¯æ˜¾è‘—å»¶é•¿ OS (10.8 vs 7.5 ä¸ªæœˆ) å’Œ PFS [[2]](#ref-pmid-37133585)ã€‚
    *   **è‚¾åŠŸèƒ½é€‚åº”æ€§**: TAS-102 ä¸»è¦ç»è‚¾æ’æ³„ï¼Œä½†åœ¨è½»ä¸­åº¦è‚¾å—æŸ (CrCl 30-89 mL/min) æ‚£è€…ä¸­**æ— éœ€è°ƒæ•´èµ·å§‹å‰‚é‡** [[5]](#ref-fda-lonsurf label)ã€‚æ‚£è€… eGFR ~39 mL/minï¼Œç¬¦åˆä½¿ç”¨æ ‡å‡†ï¼Œä½†éœ€å¯†åˆ‡ç›‘æµ‹éª¨é«“æŠ‘åˆ¶ã€‚

*   **ç»™è¯æ–¹æ¡ˆ**:
    *   TAS-102: 35 mg/mÂ² PO, bid, d1-5, d8-12, q4w (é¤åæœç”¨)ã€‚
    *   è´ä¼ç å•æŠ—: 5 mg/kg IV, q2wã€‚

*   **å‰‚é‡è°ƒæ•´**:
    *   è‹¥ CrCl é™è‡³ <30 mL/minï¼Œéœ€å‡é‡æˆ–åœè¯ã€‚

---

### ğŸŸ£ ç²¾å‡†æ²»ç–—å¤‡é€‰ (Option 3) - é¶å‘ ATM/TMB
**æ–¹æ¡ˆåç§°**: ä¸´åºŠè¯•éªŒ (ATR æŠ‘åˆ¶å‰‚) æˆ– PARP æŠ‘åˆ¶å‰‚ (è¶…é€‚åº”ç—‡)
**è¯æ®ç­‰çº§**: C (ç”Ÿç‰©æ ‡å¿—ç‰©é©±åŠ¨)

*   **ATM é¶å‘**:
    *   æ‚£è€…æºå¸¦ **ATM èƒšç³»çªå˜**ï¼Œç†è®ºä¸Šå¯¹ DNA æŸä¼¤ä¿®å¤æŠ‘åˆ¶å‰‚æ•æ„Ÿã€‚
    *   **æ¨è**: ä¼˜å…ˆå‚åŠ  **ATR æŠ‘åˆ¶å‰‚ (å¦‚ IMP9064)** çš„ä¸´åºŠè¯•éªŒ (NCT05269316)ã€‚
    *   **è¶…é€‚åº”ç—‡**: è‹¥æ— æ³•å…¥ç»„ï¼Œå¯è€ƒè™‘ **å¥¥æ‹‰å¸•åˆ© (Olaparib)** å•è¯ã€‚è™½ç„¶åœ¨ CRC ä¸­è¯æ®æœ‰é™ï¼Œä½†åœ¨ ATM çªå˜å®ä½“ç˜¤ç¯®å­è¯•éªŒä¸­æ˜¾ç¤ºç–—æ•ˆ [[3]](#ref-pmid-37852034)ã€‚éœ€æ³¨æ„ PARP æŠ‘åˆ¶å‰‚ä¼šåŠ é‡è´«è¡€ï¼Œéœ€è¯„ä¼°éª¨é«“åŠŸèƒ½ã€‚

*   **TMB-H å…ç–«é‡å¯**:
    *   é‰´äº TMB 79 mut/MBï¼Œè‹¥ä½“èƒ½å…è®¸ï¼Œå¯è€ƒè™‘ **åŒå…ç–«æ²»ç–— (Nivolumab + Ipilimumab)**ã€‚NCCN æŒ‡å—æ¨èç”¨äº TMB-H å®ä½“ç˜¤ [NCCN Guidelines]ã€‚ä½†éœ€è­¦æƒ•æ—¢å¾€å…ç–«æ²»ç–—æ— æ•ˆåŠå‰¯ä½œç”¨å²ã€‚

---

## 3. è¯ç‰©ç›¸äº’ä½œç”¨ä¸åˆå¹¶ç—‡ç®¡ç† (Critical DDIs)

æ‚£è€…æ­£åœ¨æœç”¨ï¼šç¡è‹¯åœ°å¹³ã€é˜¿æ‰˜ä¼ä»–æ±€ã€è¾¾æ ¼åˆ—å‡€ã€é˜¿å¡æ³¢ç³–ã€‚

| è¯ç‰©ç±»åˆ« | æ½œåœ¨é£é™© | å»ºè®® |
| :--- | :--- | :--- |
| **ä»–æ±€ç±» (é˜¿æ‰˜ä¼ä»–æ±€)** | **âš ï¸ è‚Œè‚‰æ¯’æ€§é£é™©**<br>KRAS G12C æŠ‘åˆ¶å‰‚ (å¦‚ Sotorasib) å¯èƒ½æ˜¯ CYP3A4 è¯±å¯¼å‰‚ï¼Œè€Œ Adagrasib æ˜¯æŠ‘åˆ¶å‰‚ã€‚æ°Ÿæ³½é›·èµ› (IBI351) è‹¥ä¸º CYP3A4 æŠ‘åˆ¶å‰‚ï¼Œä¼šæ˜¾è‘—å¢åŠ é˜¿æ‰˜ä¼ä»–æ±€è¡€è¯æµ“åº¦ï¼Œå¯¼è‡´æ¨ªçº¹è‚Œæº¶è§£é£é™©ã€‚ | å»ºè®®æš‚æ—¶åœç”¨é˜¿æ‰˜ä¼ä»–æ±€ï¼Œæˆ–æ¢ç”¨ä¸ç» CYP3A4 ä»£è°¢çš„ **ç‘èˆ’ä¼ä»–æ±€** (Rosuvastatin) å¹¶ä»ä½å‰‚é‡å¼€å§‹ã€‚ |
| **é™å‹è¯ (ç¡è‹¯åœ°å¹³)** | **âš ï¸ è¡€å‹æ³¢åŠ¨**<br>ç¡è‹¯åœ°å¹³æ˜¯ CYP3A4 åº•ç‰©ã€‚è‹¥æ°Ÿæ³½é›·èµ›å½±å“ CYP3A4ï¼Œå¯èƒ½å¯¼è‡´ä½è¡€å‹æˆ–è¡€å‹æ§åˆ¶ä¸ä½³ã€‚ | æ¯æ—¥ç›‘æµ‹è¡€å‹ã€‚è‹¥å‡ºç°ä½è¡€å‹ï¼Œéœ€è°ƒæ•´é™å‹è¯å‰‚é‡ã€‚ |
| **SGLT2 (è¾¾æ ¼åˆ—å‡€)** | **âš ï¸ è‚¾åŠŸèƒ½/è„±æ°´**<br>è¾¾æ ¼åˆ—å‡€å…·æœ‰åˆ©å°¿ä½œç”¨ï¼Œå¯èƒ½åŠ é‡è…¹æ³»å¼•èµ·çš„è„±æ°´ï¼Œè¿›è€Œæ¶åŒ–è‚¾åŠŸèƒ½ã€‚ | è‹¥å‡ºç°è…¹æ³» (Grade â‰¥1)ï¼Œç«‹å³æš‚åœè¾¾æ ¼åˆ—å‡€ï¼Œç›´è‡³è…¹æ³»ç¼“è§£ä¸”æ°´åˆçŠ¶æ€æ¢å¤ã€‚ |
| **PPI (è´¨å­æ³µæŠ‘åˆ¶å‰‚)** | **âŒ å¸æ”¶å—é˜»**<br>KRAS G12C æŠ‘åˆ¶å‰‚é€šå¸¸ä¾èµ–é…¸æ€§ç¯å¢ƒå¸æ”¶ã€‚ | è¯¢é—®æ‚£è€…æ˜¯å¦æœç”¨å¥¥ç¾æ‹‰å”‘ç­‰èƒƒè¯ã€‚è‹¥å¿…é¡»æœç”¨ï¼Œåº”é—´éš” 4-10 å°æ—¶ [[6]](#ref-fda-sotorasib label)ã€‚ |

---

## 4. å™¨å®˜åŠŸèƒ½ä¸å‰‚é‡è°ƒæ•´ (Organ Function)

### è‚¾åŠŸèƒ½ (Renal) - **ä¸»è¦é™åˆ¶å› ç´ **
*   **å½“å‰æŒ‡æ ‡**: è‚Œé… 146 Î¼mol/L (eGFR ~39 mL/min)ã€‚
*   **åˆ¤å®š**: CKD 3b æœŸã€‚
*   **è°ƒæ•´ç­–ç•¥**:
    *   **æ°Ÿæ³½é›·èµ›**: å°šæ— æ˜ç¡® eGFR <40 çš„å‰‚é‡æŒ‡å—ã€‚å»ºè®®æŒ‰æ ‡å‡†å‰‚é‡èµ·å§‹ï¼Œä½†è‹¥è‚Œé…è¾ƒåŸºçº¿å‡é«˜ >25%ï¼Œåº”æš‚åœå¹¶å‡é‡ã€‚
    *   **TAS-102**: eGFR 30-89 æ— éœ€è°ƒæ•´ã€‚è‹¥ eGFR <30ï¼Œèµ·å§‹å‰‚é‡å‡è‡³ 20 mg/mÂ² [FDA Label]ã€‚
    *   **é€ å½±å‰‚**: **ç¦æ­¢**ä½¿ç”¨ç¢˜é€ å½±å‰‚è¿›è¡Œå¢å¼º CTï¼Œä»¥å…è¯±å‘é€ å½±å‰‚è‚¾ç—…ã€‚å»ºè®®ä½¿ç”¨ **MRI** æˆ–å¹³æ‰« CT è¿›è¡Œç–—æ•ˆè¯„ä¼°ã€‚

### çš®è‚¤æ¯’æ€§ (Dermatologic)
*   **è¥¿å¦¥æ˜”å•æŠ—**: å¸¸è§ç—¤ç–®æ ·çš®ç–¹ã€‚
*   **ç®¡ç†**: é¢„é˜²æ€§ä½¿ç”¨å¤šè¥¿ç¯ç´  (100mg bid) + æ°¢åŒ–å¯çš„æ¾è½¯è†ã€‚æ³¨æ„å¤šè¥¿ç¯ç´ å¯èƒ½å¼•èµ·å…‰æ•ï¼Œéœ€é˜²æ™’ã€‚

---

## 5. ä¸æ¨èæ–¹æ¡ˆ (Not Recommended)

1.  **âŒ ç‘æˆˆéå°¼ (Regorafenib) / å†æ¬¡ä½¿ç”¨å‘‹å–¹æ›¿å°¼**:
    *   **åŸå› **: å‡ä¸ºå¤šé¶ç‚¹ TKIï¼Œå…·æœ‰æ˜ç¡®çš„è‚¾æ¯’æ€§ã€‚æ‚£è€…æ—¢å¾€å·²å‘ç”Ÿ TKI ç›¸å…³æ€¥æ€§è‚¾æŸä¼¤ï¼Œå†æ¬¡ä½¿ç”¨æ­¤ç±»è¯ç‰©å¯¼è‡´é€æé£é™©æé«˜ã€‚

2.  **âŒ å¥¥æ²™åˆ©é“‚/ä¼Šç«‹æ›¿åº·å†æŒ‘æˆ˜**:
    *   **åŸå› **: å¤šçº¿æ²»ç–—åè·ç›Šæä½ï¼Œä¸”å¥¥æ²™åˆ©é“‚æœ‰ç¥ç»æ¯’æ€§ï¼Œä¼Šç«‹æ›¿åº·æœ‰è…¹æ³»é£é™©ï¼ˆåŠ é‡è‚¾å‰æ€§è‚¾è¡°ï¼‰ã€‚

3.  **âŒ å•è¯å…ç–«æ²»ç–—**:
    *   **åŸå› **: æ—¢å¾€ä¿¡è¿ªåˆ©å•æŠ—æ²»ç–—ä»…è· SD åè¿›å±•ï¼Œä¸”æ‚£è€…ä¸º MSSã€‚å•çº¯ PD-1 æŠ‘åˆ¶å‰‚æ— æ•ˆã€‚

---

## 6. éšè®¿ä¸ç›‘æµ‹è®¡åˆ’

*   **ç¬¬ 1-2 ä¸ªæœˆ (å½“å‰)**:
    *   **æ¯å‘¨**: è¡€å¸¸è§„ã€ç”ŸåŒ– (é‡ç‚¹å…³æ³¨è‚Œé…ã€ç”µè§£è´¨ã€ç™½è›‹ç™½)ã€‚
    *   **æ¯ 2 å‘¨**: å°¿å¸¸è§„ (ç›‘æµ‹è›‹ç™½å°¿)ã€‚
    *   **ä¸´åºŠ**: æ¯æ—¥è‡ªæµ‹è¡€å‹ã€ä½“é‡ (é˜²è„±æ°´)ã€‚

*   **ç–—æ•ˆè¯„ä¼°**:
    *   **æ—¶é—´**: æ²»ç–—å¼€å§‹å 6-8 å‘¨ (çº¦ 2025 å¹´ 12 æœˆ)ã€‚
    *   **æ‰‹æ®µ**: èƒ¸éƒ¨/è…¹éƒ¨ **å¢å¼º MRI** (é¿å… CT é€ å½±å‰‚) + ç™ŒèƒšæŠ—åŸ (CEA)ã€‚

*   **ä¸‹ä¸€æ­¥å†³ç­–**:
    *   è‹¥ **SD/PR**: ç»§ç»­å½“å‰æ²»ç–—ã€‚
    *   è‹¥ **PD (è¿›å±•)**: åœç”¨æ°Ÿæ³½é›·èµ›ï¼Œä¼‘æ•´ 2 å‘¨åå¯åŠ¨ TAS-102 + è´ä¼ç å•æŠ—ï¼Œæˆ–è½¬è¯Šè‡³ ATR æŠ‘åˆ¶å‰‚ä¸´åºŠè¯•éªŒã€‚

## å‚è€ƒæ–‡çŒ®
1.  **CodeBreaK 300 (Sotorasib+Panitumumab)**: [[1]](#ref-pmid-37870968)
2.  **SUNLIGHT (TAS-102+Bevacizumab)**: [[2]](#ref-pmid-37133585)
3.  **ATM Mutation & PARP Inhibitors**: [[3]](#ref-pmid-37852034)
4.  **NCCN Guidelines Colon Cancer v1.2025**: [NCCN.org](https://www.nccn.org/guidelines)
5.  **FDA Labels**: [Sotorasib](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf), [Lonsurf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207981s008lbl.pdf)

---

## Tool Call Details

### Tool Call 1: `search_nccn`
**Timestamp:** 2026-01-20 20:25:16

**Parameters:**
```json
{
  "cancer_type": "Colon Cancer"
}
```

**Result:**
```
**NCCN æŒ‡å—æ£€ç´¢ç»“æœ**
**æŸ¥è¯¢**: Colon Cancer
**æ‰¾åˆ° 5 æ¡ç›¸å…³å†…å®¹**:
---
### 1. ï¼ˆ2025.V1ï¼‰NCCNä¸´åºŠå®è·µæŒ‡å—ï¼šç»“è‚ ç™Œ (245/1162)
**ç™Œç—‡ç±»å‹**: Colon Cancer
**ç›¸å…³åº¦**: 61.55%

[Page 62]
NCCN Guidelines Version 1.2025
Colon Cancer
Version 1.2025, 02/07/25 Â© 2025 National Comprehensive Cancer NetworkÂ® (NCCNÂ®), All rights reserved. NCCN GuidelinesÂ® and this illustration may not be reproduced in any form without the express written permission of NCCN. Note: All recommendations are category 2A unless otherwise indicated. NCCN Guidelines Index
Table of Contents
Discussion
PRINCIPLES OF APPENDICEAL ADENOCARCINOMA
COL-I
2 OF 3
Localized Disease
â€¢ Screening colonoscopy is recommended in all patients diagnosed
with AA prior to definitive resection to rule out synchronous large
polyps or cancers. â€¢ Right hemicolectomy with adequate lymphadenectomy is
recommended.

---
### 2. ï¼ˆ2025.V1ï¼‰NCCNä¸´åºŠå®è·µæŒ‡å—ï¼šç»“è‚ ç™Œ (757/1162)
**ç™Œç—‡ç±»å‹**: Colon Cancer
**ç›¸å…³åº¦**: 59.93%

[Page 156]
Version 1.2025 Â© 2025 National Comprehensive Cancer NetworkÂ© (NCCNÂ©), All rights reserved. NCCN GuidelinesÂ® and this illustration may not be reproduced in any form without the express written permission of NCCN. NCCN Guidelines Version 1.2025 
Colon Cancer 
MS-89 
as treatment recommendations can vary considerably at all stages of 
colon cancer based on these biomarker results. The recommended surgical procedure for resectable colon cancer is an en 
bloc resection and adequate lymphadenectomy. Adequate pathologic 
assessment of the resected lymph nodes is important with a goal of 
evaluating at least 12 nodes. Adjuvant chemotherapy is recommended for 
patients with stage III disease and is also an option for some patients with 
high-risk stage II disease. The preferred regimens 
... (å…± 944 å­—ç¬¦)

---
### 3. ï¼ˆ2025.V1ï¼‰NCCNä¸´åºŠå®è·µæŒ‡å—ï¼šç»“è‚ ç™Œ (21/1162)
**ç™Œç—‡ç±»å‹**: Colon Cancer
**ç›¸å…³åº¦**: 58.21%

COL-B 6 of 10
â€¢ POLE/POLD1
Bullet 4 revised: NGS of CRCs arising in patients with either germline or somatic ED PVs demonstrate an ultramutator ultra-hypermutated phenotype
identified as extremely high tumor mutational burden (TMB>50 mut/Mb >100 mut/Mb). COL-C 1 of 6
â€¢ Principles of Surgery and Locoregional Therapies
Colectomy
â—ŠBullet 2, sub-bullet 2 revised: Consider Preoperative localization is performed (eg, radiographic identification, preoperative endoscopic marking,
endoscopic landmarks) of lesion(s). â—ŠBullet 2, sub-bullet 4 revised: Minimally invasive approaches are generally not indicated for locally advanced cancer (eg, invasion into adjacent
structure) or acute bowel obstruction.... Updates in Version 1.2025 of the NCCN Guidelines for Colon Cancer from Version 6.2024 include: 

... (å…± 895 å­—ç¬¦)

---
### 4. ï¼ˆ2025.V1ï¼‰NCCNä¸´åºŠå®è·µæŒ‡å—ï¼šç»“è‚ ç™Œ (249/1162)
**ç™Œç—‡ç±»å‹**: Colon Cancer
**ç›¸å…³åº¦**: 57.66%

If a patient is not a candidate for surgery, treatment should follow 
metastatic colon cancer guidelines. The extent of cytoreduction should be individualized. Surgery is 
discouraged for high PCI, biliary obstruction, extensive disease at 
the gastrohepatic ligament/porta hepatis, extensive retroperitoneal 
disease, intraparenchymal liver lesions requiring a major 
resection, diffuse small bowel serosa/mesenteric involvement, and/
or multiple sites of small bowel obstruction. References on COL-I (3 of 3)
Systemic Therapy (COL-D)
NCCN æˆæƒåŒ»è„‰é€šæä¾›NCCNæŒ‡å—å…¨æ–‡ä¸‹è½½ã€‚6261163äº2025/02/18,11:03åœ¨åŒ»è„‰é€šå¹³å°ä¸‹è½½ï¼Œä»…ä¾›ä¸ªäººä½¿ç”¨ï¼Œä¸¥ç¦åˆ†å‘ã€‚2025 ç¾å›½å›½å®¶ç»¼åˆç™Œç—‡ç½‘ç»œç‰ˆæƒæ‰€æœ‰ã€‚

---
### 5. ï¼ˆ2025.V1ï¼‰NCCNä¸´åºŠå®è·µæŒ‡å—ï¼šç»“è‚ ç™Œ (336/1162)
**ç™Œç—‡ç±»å‹**: Colon Cancer
**ç›¸å…³åº¦**: 57.36%

[Page 81]
Version 1.2025 Â© 2025 National Comprehensive Cancer NetworkÂ© (NCCNÂ©), All rights reserved. NCCN GuidelinesÂ® and this illustration may not be reproduced in any form without the express written permission of NCCN. NCCN Guidelines Version 1.2025 
Colon Cancer 
MS-14 
However, in addition to the option of observation, the Panel includes the 
option of colectomy in patients with a completely removed, single-
specimen, sessile polyp with favorable histologic features and clear 
margins. This option is included because the literature seems to indicate 
that patients with sessile polyps may have a significantly greater incidence 
of adverse outcomes, including disease recurrence, mortality, and 
hematogenous metastasis compared with those with pedunculated polyps.

---

**æ³¨æ„**: ä»¥ä¸Šå†…å®¹æ¥è‡ª NCCN æŒ‡å— PDFï¼Œå…·ä½“æ²»ç–—æ–¹æ¡ˆè¯·ç»“åˆæœ€æ–°ç‰ˆæŒ‡å—å’Œæ‚£è€…å…·ä½“æƒ…å†µã€‚

```

### Tool Call 2: `search_fda_labels`
**Timestamp:** 2026-01-20 20:25:18

**Parameters:**
```json
{
  "drug_name": "Sotorasib"
}
```

**Result:**
```
**FDA è¯å“è¯´æ˜ä¹¦**

**è¯ç‰©**: SOTORASIB
**å•†å“å**: LUMAKRAS
**ç”Ÿäº§å•†**: Amgen Inc

### é€‚åº”ç—‡
1 INDICATIONS AND USAGE LUMAKRAS is an inhibitor of the RAS GTPase family indicated for: KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.1 ) KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC) In combination with panitumumab, for the treatment of adult patients with KRAS G12C-mutated mCRC as determined by an FDA approved-test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. ( 1.2 ) 1.1 KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) LUMAKRAS as a single agent is indicated for the treatment of adult patients with KRAS G12C -mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test [see Dosage and Administration (2.1) ] , who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR) [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.2 KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC) LUMAKRAS, in combination with panitumumab, is indicated for the treatment of adult patients with KRAS G12C -mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy [see Dosage and Administr

### å‰‚é‡ä¸ç”¨æ³•
2 DOSAGE AND ADMINISTRATION Recommended dosage as a single agent for NSCLC and in combination with panitumumab for mCRC: 960 mg orally once daily. ( 2.2 ) Swallow tablets whole with or without food. ( 2.2 ) 2.1 Patient Selection KRAS G12C-mutated Locally Advanced or Metastatic NSCLC Select patients for treatment of locally advanced or metastatic NSCLC with LUMAKRAS based on the presence of KRAS G12C mutation in tumor or plasma specimens. If no mutation is detected in a plasma specimen, test tumor tissue [see Clinical Studies (14.1) ]. KRAS G12C-mutated mCRC Select patients for treatment of mCRC based on the presence of KRAS G12C mutation in tumor specimens [see Clinical Studies (14.2) ]. Information on FDA-approved tests for the detection of KRAS G12C mutations is available at: http://www.fda.gov/CompanionDiagnostics. 2.2 Recommended Dosage and Administration LUMAKRAS as a Single Agent for KRAS G12C-mutated Locally Advanced or Metastatic NSCLC The recommended dosage of LUMAKRAS is 960 mg (three 320 mg tablets or four 240 mg tablets or eight 120 mg tablets) orally once daily until disease progression or unacceptable toxicity. LUMAKRAS in Combination with Panitumumab for KRAS G12C-mutated mCRC The recommended dosage of LUMAKRAS is 960 mg (three 320 mg tablets or four 240 mg tablets or eight 120 mg tablets) orally once daily in combination with panitumumab until disease progression or unacceptable toxicity. Administer the first dose of LUMAKRAS prior to first panitumumab infusion. Refer to the panitumumab full prescribing information for recommended panitumumab dosage information. Take the daily dose of LUMAKRAS at the same time each day with or without food [see Clinical Pharmacology (12.3) ] . Swallow tablets whole. Do not chew, crush or split tablets . If a dose of LUMAKRAS is missed by more than 6 hours, take the next dose as prescribed the next day. Do not take 2 doses at the same time to make up for the missed dose. If vomiting occurs after taking LUMAKRAS, do no

### è­¦å‘Šä¸æ³¨æ„äº‹é¡¹
5 WARNINGS AND PRECAUTIONS Hepatotoxicity: Monitor liver function tests every 3 weeks for the first 3 months of treatment then once monthly as clinically indicated. Consider administering systemic corticosteroids and withhold, reduce the dose, or permanently discontinue LUMAKRAS based on the severity. ( 2.3 , 5.1 ) Interstitial Lung Disease (ILD)/Pneumonitis: Monitor for new or worsening pulmonary symptoms. Immediately withhold LUMAKRAS for suspected ILD/pneumonitis and permanently discontinue if no other potential causes of ILD/pneumonitis are identified. ( 2.3 , 5.2 ) 5.1 Hepatotoxicity LUMAKRAS can cause hepatotoxicity and increased alanine aminotransferase (ALT) or increased aspartate aminotransferase (AST) which may lead to drug-induced liver injury and hepatitis. In the pooled safety population of patients with NSCLC who received single agent LUMAKRAS 960 mg [see Adverse Reactions (6.1) ] , hepatotoxicity occurred in 27% of patients, of which 16% were Grade â‰¥ 3. Among patients with hepatotoxicity who required dosage modifications, 64% required treatment with corticosteroids. In this pooled safety population of patients with NSCLC who received single agent LUMAKRAS 960 mg, 17% of patients who received LUMAKRAS had increased ALT/increased AST; of which 9% were Grade â‰¥ 3. The median time to first onset of increased ALT/AST was 6.3 weeks (range: 0.4 to 42). Increased ALT/AST leading to dose interruption or reduction occurred in 9% of patients treated with LUMAKRAS. LUMAKRAS was permanently discontinued due to increased ALT/AST in 2.7% of patients. Drug-induced liver injury occurred in 1.6% (all grades) including 1.3% (Grade â‰¥ 3). In this pooled safety population of patients with NSCLC who received single agent LUMAKRAS 960 mg, a total of 40% patients with recent (â‰¤ 3 months) immunotherapy prior to starting LUMAKRAS had an event of hepatotoxicity. An event of hepatotoxicity was observed in 18% of patients who started LUMAKRAS more than 3 months after last dose of i

### ç¦å¿Œç—‡
4 CONTRAINDICATIONS None. None. ( 4 )

### è¯ç‰©ç›¸äº’ä½œç”¨
7 DRUG INTERACTIONS Acid-Reducing Agents: Avoid coadministration with proton pump inhibitors (PPIs) and H 2 receptor antagonists. If an acid-reducing agent cannot be avoided, administer LUMAKRAS 4 hours before or 10 hours after a local antacid. ( 2.4 , 7.1 ) Strong CYP3A4 Inducers: Avoid coadministration with strong CYP3A4 inducers. ( 7.1 ) CYP3A4 Substrates: Avoid coadministration with CYP3A4 substrates for which minimal concentration changes may lead to therapeutic failures of the substrate. If coadministration cannot be avoided, adjust the substrate dosage in accordance to its Prescribing Information. ( 7.2 ) P-gp substrates: Avoid coadministration with P-gp substrates for which minimal concentration changes may lead to serious toxicities. If coadministration cannot be avoided, decrease the substrate dosage in accordance to its Prescribing Information. ( 7.2 ) 7.1 Effects of Other Drugs on LUMAKRAS Acid-Reducing Agents The solubility of sotorasib is pH-dependent. Coadministration of LUMAKRAS with gastric acid-reducing agents decreased sotorasib concentrations [see Clinical Pharmacology (12.3) ] , which may reduce the efficacy of sotorasib. Avoid coadministration of LUMAKRAS with proton pump inhibitors (PPIs), H 2 receptor antagonists, and locally acting antacids. If coadministration with an acid-reducing agent cannot be avoided, administer LUMAKRAS 4 hours before or 10 hours after administration of a locally acting antacid [see Dosage and Administration (2.4) ] . Strong CYP3A4 Inducers Sotorasib is a CYP3A4 substrate. Coadministration of LUMAKRAS with a strong CYP3A4 inducer decreased sotorasib concentrations [see Clinical Pharmacology (12.3) ] , which may reduce the efficacy of sotorasib. Avoid coadministration of LUMAKRAS with strong CYP3A4 inducers . 7.2 Effects of LUMAKRAS on Other Drugs CYP3A4 Substrates Sotorasib is a CYP3A4 inducer. Coadministration of LUMAKRAS with a CYP3A4 substrate decreased its plasma concentrations [see Clinical Pharmacology (12.3) ] 

### ä¸è‰¯ååº”
6 ADVERSE REACTIONS The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: Hepatotoxicity [see Warnings and Precautions (5.1) ] Interstitial Lung Disease (ILD)/Pneumonitis [see Warnings and Precautions (5.2) ] Single agent in NSCLC: The most common adverse reactions (â‰¥ 20%) were diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity, and cough. The most common laboratory abnormalities (â‰¥ 25%) were decreased lymphocytes, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, decreased calcium, increased alkaline phosphatase, increased urine protein, and decreased sodium. ( 6.1 ) In combination with panitumumab in CRC: The most common adverse reactions (â‰¥ 20%) in clinical trials of LUMAKRAS in combination with panitumumab are rash, dry skin, diarrhea, stomatitis, fatigue and musculoskeletal pain. The most common Grade 3 or 4 laboratory abnormalities in â‰¥ 2 patients (4.3%) were decreased magnesium, decreased potassium, decreased corrected calcium, and increased potassium. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Amgen Inc. at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The pooled safety population described in the WARNINGS AND PRECAUTIONS reflect exposure to LUMAKRAS as a single agent at 960 mg orally once daily until disease progression or unacceptable toxicity in 549 patients with NSCLC with KRAS G12C mutation in the following trials: CodeBreaK 200 (NCT04303780), CodeBreaK 100 (NCT03600883), CodeBreaK 101 (NCT04185883) and CodeBreaK 105 (NCT04380753). Among these 549 patients who received LUMAKRAS, 44% were expo

**å‚è€ƒ**: https://labels.fda.gov (æœç´¢ SOTORASIB)
```

### Tool Call 3: `search_fda_labels`
**Timestamp:** 2026-01-20 20:25:18

**Parameters:**
```json
{
  "drug_name": "Adagrasib"
}
```

**Result:**
```
**FDA è¯å“è¯´æ˜ä¹¦**

**è¯ç‰©**: ADAGRASIB
**å•†å“å**: KRAZATI
**ç”Ÿäº§å•†**: Mirati Therapeutics, Inc

### é€‚åº”ç—‡
1 INDICATIONS AND USAGE KRAZATI is an inhibitor of the RAS GTPase family indicated for: Non-small cell lung cancer (NSCLC)* â€¢ As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. ( 1.1 ) Colorectal cancer (CRC)* â€¢ In combination with cetuximab, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic CRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. ( 1.2 ) *These indications are approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for these indications may be contingent upon verification and description of a clinical benefit in confirmatory trials. ( 1.1 , 1.2 ) 1.1 KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer KRAZATI, as a single-agent, is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test [see Dosage and Administration (2.1) ] , who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR) [see Clinical Studies (14.1) ]. Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial. 1.2 KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer KRAZATI in combination with cetuximab is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC), as determined by an FDA-approved test [see Dosage and Administration (2.1) ] , who have received prior treatment with fluoropyrimidine-, oxaliplatin-, an

### å‰‚é‡ä¸ç”¨æ³•
2 DOSAGE AND ADMINISTRATION â€¢ Recommended dosage as a single agent for NSCLC and in combination with cetuximab for CRC: 600 mg orally twice daily. ( 2.2 ) â€¢ Swallow tablets whole with or without food. ( 2.2 ) 2.1 Patient Selection Non-Small Cell Lung Cancer Select patients for treatment of locally advanced or metastatic NSCLC with KRAZATI based on the presence of KRAS G12C mutation in plasma or tumor specimens [see Clinical Studies (14.1) ] . If no mutation is detected in a plasma specimen, test tumor tissue. Colorectal Cancer Select patients for treatment of locally advanced or metastatic CRC with KRAZATI based on the presence of KRAS G12C mutation in tumor specimens [see Clinical Studies (14.2) ] . Information on FDA-approved tests for the detection of a KRAS G12C mutation is available at: https://www.fda.gov/CompanionDiagnostics 2.2 Recommended Dosage The recommended dosage of KRAZATI as a single agent or in combination with cetuximab is 600 mg orally twice daily until disease progression or unacceptable toxicity. Refer to the cetuximab prescribing information for cetuximab dosage information [see Clinical Studies (14.2) ]. Take KRAZATI at the same time every day with or without food [see Clinical Pharmacology (12.3) ]. Swallow tablets whole. Do not chew, crush or split tablets. If vomiting occurs after taking KRAZATI, do not take an additional dose. Resume dosing at the next scheduled time. If a dose is inadvertently missed, it should be skipped if greater than 4 hours have elapsed from the expected dosing time. Resume dosing at the next scheduled time. 2.3 Dosage Modifications for Adverse Reactions Recommended dose reductions for adverse reactions for use of KRAZATI as a single agent or in combination with cetuximab are outlined in Table 1. If adverse reactions occur, a maximum of two dose reductions are permitted. Permanently discontinue KRAZATI in patients who are unable to tolerate 600 mg once daily. Table 1: Recommended KRAZATI Dosage Reductions for Adverse

### è­¦å‘Šä¸æ³¨æ„äº‹é¡¹
5 WARNINGS AND PRECAUTIONS â€¢ Gastrointestinal Adverse Reactions : Monitor patients for diarrhea, nausea and vomiting and provide supportive care as needed. Withhold, reduce the dose or permanently discontinue based on severity. ( 2.3 , 5.1 ) â€¢ QTc Interval Prolongation: Avoid concomitant use of KRAZATI with other products with a known potential to prolong the QTc interval. Monitor ECG and electrolytes particularly potassium and magnesium, in patients at risk, and in patients taking medications known to prolong the QT interval. Correct electrolyte abnormalities. Withhold, reduce the dose, or permanently discontinue based on severity. ( 2.3 , 5.2 ) â€¢ Hepatotoxicity: Monitor liver laboratory tests prior to the start of KRAZATI and monthly for 3 months after and as clinically indicated. Reduce the dose, withhold, or permanently discontinue based on severity. ( 2.3 , 5.3 ) â€¢ Interstitial Lung Disease (ILD) / Pneumonitis: Monitor for new or worsening respiratory symptoms. Withhold KRAZATI for suspected ILD/pneumonitis and permanently discontinue if no other potential causes of ILD/pneumonitis are identified. ( 2.3 , 5.4 ) 5.1 Gastrointestinal Adverse Reactions KRAZATI can cause severe gastrointestinal adverse reactions. In the pooled safety population [see Adverse Reactions (6.1) ] , who received single-agent KRAZATI, serious gastrointestinal adverse reactions observed were gastrointestinal bleeding in 3.8% including 0.8% Grade 3 or 4, gastrointestinal obstruction in 1.6% including 1.4% Grade 3 or 4, colitis in 0.5% including 0.3% Grade 3, ileus in 0.5%, and stenosis in 0.3%. In addition, nausea, diarrhea, or vomiting occurred in 89% of 366 patients, including 9% Grade 3. Nausea, diarrhea, or vomiting led to dosage interruption or dose reduction in 29% of patients and permanent discontinuation of adagrasib in 0.3%. In patients who received KRAZATI in combination with cetuximab [see Adverse Reactions (6.1) ] , serious gastrointestinal adverse reactions included gastrointes

### ç¦å¿Œç—‡
4 CONTRAINDICATIONS None. None. ( 4 )

### è¯ç‰©ç›¸äº’ä½œç”¨
7 DRUG INTERACTIONS See full prescribing information for clinically significant drug interactions with KRAZATI. ( 7 ) â€¢ Strong CYP3A4 Inducers : Avoid concomitant use. ( 7.1 ) â€¢ Strong CYP3A4 Inhibitors : Avoid concomitant use until adagrasib concentrations have reached steady state. ( 7.1 ) â€¢ Sensitive CYP3A4 Substrates : Avoid concomitant use with sensitive CYP3A4 substrates. ( 7.2 ) â€¢ Sensitive CYP2C9 or CYP2D6 Substrates or P-gp Substrates : Avoid concomitant use with sensitive CYP2C9 or CYP2D6 substrates or P-gp substrates where minimal concentration changes may lead to serious adverse reactions. ( 7.2 ) â€¢ Drugs That Prolong QT Interval : Avoid concomitant use with KRAZATI. ( 7.3 ) 7.1 Effects of Other Drugs on KRAZATI Strong CYP3A4 Inducers Avoid concomitant use of KRAZATI with strong CYP3A inducers. Adagrasib is a CYP3A4 substrate. Concomitant use of KRAZATI with a strong CYP3A inducer reduces adagrasib exposure [see Clinical Pharmacology (12.3) ] , which may reduce the effectiveness of KRAZATI. Strong CYP3A4 Inhibitors Avoid concomitant use of KRAZATI with strong CYP3A inhibitors until adagrasib concentrations have reached steady state (after approximately 8 days). Adagrasib is a CYP3A4 substrate. If adagrasib concentrations have not reached steady state, concomitant use of a strong CYP3A inhibitor will increase adagrasib concentrations, [see Clinical Pharmacology (12.3) ], which may increase the risk of KRAZATI adverse reactions. 7.2 Effects of KRAZATI on Other Drugs Sensitive CYP3A Substrates Avoid concomitant use of KRAZATI with sensitive CYP3A substrates unless otherwise recommended in the Prescribing Information for these substrates. Adagrasib is a CYP3A inhibitor. Concomitant use with KRAZATI increases exposure of CYP3A substrates [see Clinical Pharmacology (12.3) ] , which may increase the risk of adverse reactions related to these substrates. Sensitive CYP2C9 Substrates Avoid concomitant use of KRAZATI with sensitive CYP2C9 substrates where minimal c

### ä¸è‰¯ååº”
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: â€¢ Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.1) ] â€¢ QTc Interval Prolongation [see Warnings and Precautions (5.2) ] â€¢ Hepatotoxicity [see Warnings and Precautions (5.3) ] â€¢ Interstitial Lung Disease (ILD)/Pneumonitis [see Warnings and Precautions (5.4) ] â€¢ Single agent use in NCSLC: The most common adverse reactions (â‰¥ 25%) were nausea, diarrhea, vomiting, fatigue, musculoskeletal pain, hepatotoxicity, renal impairment, edema, dyspnea, and decreased appetite. The most common (â‰¥ 2%) Grade 3 or 4 laboratory abnormalities were decreased lymphocytes, decreased hemoglobin, increased alanine aminotransferase, increased aspartate aminotransferase, hypokalemia, hyponatremia, increased lipase, decreased leukocytes, decreased neutrophils and increased alkaline phosphatase. ( 6.1 ) â€¢ In combination with cetuximab in CRC: The most common adverse reactions (â‰¥ 25%) were rash, nausea, diarrhea, vomiting, fatigue, musculoskeletal pain, hepatotoxicity, headache, dry skin, abdominal pain, decreased appetite, edema, anemia, and cough. The most common (â‰¥ 2%) Grade 3 or 4 laboratory abnormalities were decreased lymphocytes, decreased potassium, decreased magnesium, decreased hemoglobin, increased aspartate aminotransferase, increased lipase, decreased albumin, and increased alanine aminotransferase. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The pooled safety population described in the WARNINGS AND PRECAUTIONS reflect exposure to adagrasib as a single agent 

**å‚è€ƒ**: https://labels.fda.gov (æœç´¢ ADAGRASIB)
```

### Tool Call 4: `search_fda_labels`
**Timestamp:** 2026-01-20 20:25:18

**Parameters:**
```json
{
  "drug_name": "Cetuximab"
}
```

**Result:**
```
**FDA è¯å“è¯´æ˜ä¹¦**

**è¯ç‰©**: CETUXIMAB
**å•†å“å**: ERBITUX
**ç”Ÿäº§å•†**: ImClone LLC

### é€‚åº”ç—‡
1 INDICATIONS AND USAGE ERBITUX Â® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of: Head and Neck Cancer Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. ( 1.1 , 14.1 ) Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. ( 1.1 , 14.1 ) Recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy. ( 1.1 , 14.1 ) Colorectal Cancer K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with FOLFIRI for first-line treatment, in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy, as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan. ( 1.2 , 5.7 , 12.1 , 14.2 ) Limitations of Use: ERBITUX is not indicated for treatment of Ras-mutant colorectal cancer or when the results of the Ras mutation tests are unknown. ( 5.7 ) BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.3 ) 1.1 Squamous Cell Carcinoma of the Head and Neck (SCCHN) ERBITUX Â® is indicated: in combination with radiation therapy for the initial treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN). in combination with platinum-based therapy with fluorouracil for the first-line treatment of patients with recurrent locoregional disease or metastatic SCCHN. as a single-agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed. 1.2 K-Ras Wild-type, EGFR-expressing Colorectal Cancer (CRC)

### å‰‚é‡ä¸ç”¨æ³•
2 DOSAGE AND ADMINISTRATION Premedicate with an H 1 receptor antagonist. ( 2.4 ) In Combination With Radiation Therapy: Initial dose: 400 mg/m 2 administered as a 120-minute intravenous infusion one week prior to initiating a course of radiation therapy. ( 2.2 ) Subsequent doses: 250 mg/m 2 administered as a 60-minute infusion every week for the duration of radiation therapy (6â€“7 weeks). ( 2.2 ) Complete ERBITUX administration 1 hour prior to radiation therapy. ( 2.2 ) As Single-Agent or in Combination With Chemotherapy: Weekly: Administer initial dose of 400 mg/m 2 as a 120-minute intravenous infusion, and subsequent doses of 250 mg/m 2 infused over 60 minutes once weekly. ( 2.2 , 2.3 ) Biweekly: Administer 500 mg/m 2 as a 120-minute intravenous infusion every two weeks. ( 2.2 , 2.3 ) Complete ERBITUX administration 1 hour prior to chemotherapy. Continue treatment until disease progression or unacceptable toxicity. ( 2.2 , 2.3 ) See full prescribing information for dosage adjustments for adverse reactions. ( 2.5 ) 2.1 Patient Selection Select patients with metastatic colorectal cancer (CRC) for treatment with ERBITUX based on the presence of: Ras wild-type, EGFR-expressing CRC [see Clinical Studies ( 14.2 )], or BRAF V600E mutation-positive metastatic CRC [see Clinical Studies ( 14.3 )] Information on FDA-approved tests for the detection of K-Ras or BRAF V600E mutations in CRC in patients with metastatic CRC is available at: http://www.fda.gov/CompanionDiagnostics. 2.2 Recommended Dosage for Squamous Cell Carcinoma of the Head and Neck (SCCHN) In combination with radiation therapy Initial dose: 400 mg/m 2 administered as a 120-minute intravenous infusion one week prior to initiating a course of radiation therapy. Subsequent doses: 250 mg/m 2 administered as a 60-minute infusion every week for the duration of radiation therapy (6â€“7 weeks). Complete ERBITUX administration 1 hour prior to radiation therapy. As a single-agent or in combination with platinum-based thera

### âš ï¸ é»‘æ¡†è­¦å‘Š
WARNING: INFUSION REACTIONS and CARDIOPULMONARY ARREST Infusion Reactions: ERBITUX can cause serious and fatal infusion reactions [see Warnings and Precautions ( 5.1 ), Adverse Reactions ( 6 )] . Immediately interrupt and permanently discontinue ERBITUX for serious infusion reactions [see Dosage and Administration ( 2.5 )] . Cardiopulmonary Arrest: Cardiopulmonary arrest or sudden death occurred in patients with squamous cell carcinoma of the head and neck receiving ERBITUX with radiation therapy or a cetuximab product with platinum-based therapy and fluorouracil. Monitor serum electrolytes, including serum magnesium, potassium, and calcium, during and after ERBITUX administration [see Warnings and Precautions ( 5.2 , 5.6 )] . WARNING: INFUSION REACTIONS and CARDIOPULMONARY ARREST See full prescribing information for complete boxed warning. ERBITUX can cause serious and fatal infusion reactions. ( 5.1 , 6 ) Immediately interrupt and permanently discontinue ERBITUX for serious infusion reactions. ( 2.5 ) Cardiopulmonary arrest or sudden death occurred in patients with squamous cell carcinoma of the head and neck receiving ERBITUX with radiation therapy or with a cetuximab product with platinum-based therapy and fluorouracil. Monitor serum electrolytes, including serum magnesium, potassium, and calcium, during and after ERBITUX administration. ( 5.2 , 5.6 )

### è­¦å‘Šä¸æ³¨æ„äº‹é¡¹
5 WARNINGS AND PRECAUTIONS Infusion Reactions: Monitor patients following infusion. Immediately stop and permanently discontinue ERBITUX for serious infusion reactions. ( 2.5 , 5.1 ) Cardiopulmonary Arrest: Monitor serum electrolytes during and after ERBITUX. ( 5.2 , 5.6 ) Pulmonary Toxicity: Interrupt or permanently discontinue for acute onset or worsening of pulmonary symptoms. ( 2.5 , 5.3 ) Dermatologic Toxicity: Monitor for dermatologic toxicities or infectious sequelae. Limit sun exposure. ( 2.5 , 5.4 ) Hypomagnesemia and Accompanying Electrolyte Abnormalities: Monitor during treatment and for at least 8 weeks following the completion. Replete electrolytes as necessary. ( 5.6 ) Increased tumor progression, increased mortality, or lack of benefit observed in patients with Ras-mutant mCRC. ( 5.7 ) Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of potential risk to the fetus and to use effective contraception. ( 5.8 , 8.1 , 8.3 ) 5.1 Infusion Reactions ERBITUX can cause serious and fatal infusion reactions. Infusion reactions of any grade occurred in 8.4% of 1373 patients who received ERBITUX across clinical trials. Severe (Grades 3 and 4) infusion reactions occurred in 2.2% of patients [see Adverse Reactions ( 6.1 )] . Signs and symptoms included rapid onset of airway obstruction (bronchospasm, stridor, hoarseness), hypotension, shock, loss of consciousness, myocardial infarction, and/or cardiac arrest. The risk of anaphylactic reactions may be increased in patients with a history of tick bites, red meat allergy, or in the presence of IgE antibodies directed against galactose-Î±-1,3-galactose (alpha-gal). Consider testing patients for alpha-gal IgE antibodies using FDA-cleared methods prior to initiating ERBITUX. Negative results for alpha-gal antibodies do not rule out the risk of severe infusion reactions. Approximately 90% of severe infusion reactions occurred with the first infusion despite premedication with antihistamines. Infusion reactions may

### ç¦å¿Œç—‡
4 CONTRAINDICATIONS None. None. ( 4 )

### ä¸è‰¯ååº”
6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the label: Infusion reactions [see Warnings and Precautions ( 5.1 )] . Cardiopulmonary arrest [see Warnings and Precautions ( 5.2 )] . Pulmonary toxicity [see Warnings and Precautions ( 5.3 )] . Dermatologic toxicity [see Warnings and Precautions ( 5.4 )] . Hypomagnesemia and Electrolyte Abnormalities [see Warnings and Precautions ( 5.6 )] . The most common adverse reactions (incidence â‰¥25%) with Erbitux as a single-agent or in combination with radiotherapy or chemotherapy (FOLFIRI, Irinotecan and 5-Fluorouracil/Platinum) are: cutaneous adverse reactions (including rash, pruritus, and nail changes), headache, diarrhea, and infection. ( 6 ) The most common adverse reactions (>25%) for ERBITUX, in combination with encorafenib, are fatigue, nausea, diarrhea, dermatitis acneiform, abdominal pain, decreased appetite, arthralgia, and rash. ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described in Warnings and Precautions reflect exposure to ERBITUX in 1373 patients with SCCHN or CRC enrolled in clinical trials and treated at the recommended dosage for a median of 7 to 14 weeks [see Clinical Studies ( 14.1 , 14.2 )] . The most common adverse reactions in clinical trials with ERBITUX as a single-agent or in combination with radiotherapy or chemotherapy [FOLFIRI, irinotecan and 5-fluorouracil/platinum] (incidence â‰¥25%) include cutaneous adverse reactions (including rash, pruritus, and nail changes), headache, diarrhea, and infection. Squamous Cell Carcinoma of 

**å‚è€ƒ**: https://labels.fda.gov (æœç´¢ CETUXIMAB)
```

### Tool Call 5: `search_fda_labels`
**Timestamp:** 2026-01-20 20:25:19

**Parameters:**
```json
{
  "drug_name": "Trifluridine and Tipiracil"
}
```

**Result:**
```
**FDA è¯å“è¯´æ˜ä¹¦**

**è¯ç‰©**: TRIFLURIDINE AND TIPIRACIL
**å•†å“å**: LONSURF
**ç”Ÿäº§å•†**: Taiho Pharmaceutical Co., Ltd.

### é€‚åº”ç—‡
1 INDICATIONS AND USAGE LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of adult patients with: metastatic colorectal cancer as a single agent or in combination with bevacizumab who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. ( 1.1 ) metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. ( 1.2 ) 1.1 Metastatic Colorectal Cancer LONSURF, as a single agent or in combination with bevacizumab, is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. 1.2 Metastatic Gastric Cancer LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

### å‰‚é‡ä¸ç”¨æ³•
2 DOSAGE AND ADMINISTRATION Recommended Dosage : 35 mg/m 2 /dose orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle. ( 2.1 ) 2.1 Recommended Dosage The recommended dosage of LONSURF as a single agent or in combination with bevacizumab is 35 mg/m 2 up to a maximum of 80 mg per dose (based on the trifluridine component) orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle until disease progression or unacceptable toxicity. Round dose to the nearest 5 mg increment. Refer to the Prescribing Information for bevacizumab dosing information. Instruct patients to swallow LONSURF tablets whole. Instruct patients not to retake doses of LONSURF that are vomited or missed and to continue with the next scheduled dose. LONSURF is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1 Table 1 shows the calculated initial daily dose based on body surface area (BSA). Table 1: Recommended Dosage According to Body Surface Area (BSA) BSA (m2) Total daily dose (mg) Dose (mg) administered twice daily Tablets per dose 15 mg 20 mg < 1.07 70 35 1 1 1.07 â€“ 1.22 80 40 0 2 1.23 â€“ 1.37 90 45 3 0 1.38 â€“ 1.52 100 50 2 1 1.53 â€“ 1.68 110 55 1 2 1.69 â€“ 1.83 120 60 0 3 1.84 â€“ 1.98 130 65 3 1 1.99 â€“ 2.14 140 70 2 2 2.15 â€“ 2.29 150 75 1 3 â‰¥2.30 160 80 0 4 2.2 Dosage Modifications for Adverse Reactions Obtain complete blood cell counts prior to and on Day 15 of each cycle [see Warnings and Precautions (5.1) ] . Do not initiate the cycle of LONSURF until: Absolute neutrophil count (ANC) greater than or equal to 1,500/mm 3 or febrile neutropenia is resolved Platelets greater than or equal to 75,000/mm 3 Grade 3 or 4 non-hematological adverse reactions are resolved to Grade 0 or 1 Within a treatment cycle, withhold LONSURF for any of the following: Absolute neutrophil count (ANC) less than 500/mm 3 or febrile neutropenia Platelets less than 50,000/mm 3 Grade 3 or 4 non-hematologic adverse reaction After 

### è­¦å‘Šä¸æ³¨æ„äº‹é¡¹
5 WARNINGS AND PRECAUTIONS Severe Myelosuppression: Obtain complete blood counts prior to and on Day 15 of each cycle. Withhold and resume at next lower LONSURF dosage as recommended. ( 2.1 , 5.1 ) Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. ( 5.2 , 8.1 , 8.3 ) 5.1 Severe Myelosuppression In the 1114 patients who received LONSURF as a single agent, LONSURF caused severe or life-threatening myelosuppression (Grade 3-4) consisting of neutropenia (38%), anemia (17%), thrombocytopenia (4%) and febrile neutropenia (3%). Three patients (0.3%) died due to neutropenic infection/sepsis; four other patients (0.5%) died due to septic shock. A total of 14% of patients received granulocyte-colony stimulating factors. In the 246 patients who received LONSURF in combination with bevacizumab, LONSURF caused severe or life-threatening myelosuppression (Grade 3-4) consisting of neutropenia (52%), anemia (5%), thrombocytopenia (4%) and febrile neutropenia (0.4%). One patient (0.4%) died due to abdominal sepsis and two other patients (0.8%) died due to septic shock. A total of 29% of patients received granulocyte-colony stimulating factors. Obtain complete blood counts prior to and on Day 15 of each cycle of LONSURF and more frequently as clinically indicated. Withhold LONSURF for severe myelosuppression and resume at the next lower dosage [see Dosage and Administration (2.2) ] . 5.2 Embryo-Fetal Toxicity Based on animal studies and its mechanism of action, LONSURF can cause fetal harm when administered to a pregnant woman. Trifluridine/tipiracil caused embryo-fetal lethality and embryo-fetal toxicity in pregnant rats when orally administered during gestation at dosage levels resulting in exposures lower than those achieved at the recommended dosage of 35 mg/m 2 twice daily. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to u

### ç¦å¿Œç—‡
4 CONTRAINDICATIONS None. None. ( 4 )

### ä¸è‰¯ååº”
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Severe Myelosuppression [see Warnings and Precautions (5.1) ] The most common adverse reactions or laboratory abnormalities for single agent LONSURF (â‰¥10%) are neutropenia, anemia, thrombocytopenia, fatigue, nausea, decreased appetite, diarrhea, vomiting, abdominal pain, and pyrexia. ( 6.1 ) The most common adverse reactions or laboratory abnormalities for LONSURF in combination with bevacizumab (â‰¥20%) are neutropenia, anemia, thrombocytopenia, fatigue, nausea, increased AST, increased ALT, increased alkaline phosphatase, decreased sodium, diarrhea, abdominal pain, and decreased appetite. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Taiho Oncology, Inc. at 1-844-878-2446 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described in the WARNINGS AND PRECAUTIONS section and below reflect exposure to LONSURF at the recommended dose in 533 patients with metastatic colorectal cancer in RECOURSE, 246 patients with metastatic colorectal cancer treated with LONSURF as monotherapy in SUNLIGHT and 335 patients with metastatic gastric cancer in TAGS. Among the 1114 patients who received LONSURF as a single agent, 12% were exposed for 6 months or longer and 1% were exposed for 12 months or longer. The most common adverse reactions or laboratory abnormalities (â‰¥10%) were neutropenia, anemia, thrombocytopenia, fatigue, nausea, decreased appetite, diarrhea, vomiting, abdominal pain, and pyrexia. Among the 246 patients with metastatic colorectal cancer treated with LONSURF in combination with bevacizumab in SUNLIGHT, 39% were exposed for 6 months or longer, 

**å‚è€ƒ**: https://labels.fda.gov (æœç´¢ TRIFLURIDINE AND TIPIRACIL)
```

### Tool Call 6: `search_rxnorm`
**Timestamp:** 2026-01-20 20:25:25

**Parameters:**
```json
{
  "drug_name": "Sotorasib",
  "check_interactions": [
    "Atorvastatin",
    "Nifedipine",
    "Dapagliflozin",
    "Acarbose"
  ]
}
```

**Result:**
```
**RxNorm è¯ç‰©æŸ¥è¯¢ç»“æœ**

**è¯ç‰©**: Sotorasib
**RxCUI**: 2550714

### è¯ç‰©ç›¸äº’ä½œç”¨ (FDA è¯´æ˜ä¹¦)

*æ³¨: RxNorm æ— æ•°æ®ï¼Œä»¥ä¸‹ä¿¡æ¯æ¥è‡ª FDA è¯å“è¯´æ˜ä¹¦*

7 DRUG INTERACTIONS Acid-Reducing Agents: Avoid coadministration with proton pump inhibitors (PPIs) and H 2 receptor antagonists. If an acid-reducing agent cannot be avoided, administer LUMAKRAS 4 hours before or 10 hours after a local antacid. ( 2.4 , 7.1 ) Strong CYP3A4 Inducers: Avoid coadministration with strong CYP3A4 inducers. ( 7.1 ) CYP3A4 Substrates: Avoid coadministration with CYP3A4 substrates for which minimal concentration changes may lead to therapeutic failures of the substrate. If coadministration cannot be avoided, adjust the substrate dosage in accordance to its Prescribing Information. ( 7.2 ) P-gp substrates: Avoid coadministration with P-gp substrates for which minimal concentration changes may lead to serious toxicities. If coadministration cannot be avoided, decrease the substrate dosage in accordance to its Prescribing Information. ( 7.2 ) 7.1 Effects of Other Drugs on LUMAKRAS Acid-Reducing Agents The solubility of sotorasib is pH-dependent. Coadministration of LUMAKRAS with gastric acid-reducing agents decreased sotorasib concentrations [see Clinical Pharmacology (12.3) ] , which may reduce the efficacy of sotorasib. Avoid coadministration of LUMAKRAS with proton pump inhibitors (PPIs), H 2 receptor antagonists, and locally acting antacids. If coadministration with an acid-reducing agent cannot be avoided, administer LUMAKRAS 4 hours before or 10 hours after administration of a locally acting antacid [see Dosage and Administration (2.4) ] . Strong CYP3A4 Inducers Sotorasib is a CYP3A4 substrate. Coadministration of LUMAKRAS with a strong CYP3A4 inducer decreased sotorasib concentrations [see Clinical Pharmacology (12.3) ] , which may reduce the efficacy of sotorasib. Avoid coadministration of LUMAKRAS with strong CYP3A4 inducers . 7.2 Effects of LUMAKRAS on Other Drugs CYP3A4 Substrates Sotorasib is a CYP3A4 inducer. Coadministration of LUMAKRAS with a CYP3A4 substrate decreased its plasma concentrations [see Clinical Pharmacology (12.3) ] 

**å‚è€ƒ**: https://rxnav.nlm.nih.gov
```

### Tool Call 7: `search_pubmed`
**Timestamp:** 2026-01-20 20:25:26

**Parameters:**
```json
{
  "query": "Fulzerasib IBI351 colorectal cancer renal safety"
}
```

**Result:**
```
**PubMed æœç´¢ç»“æœ**

**æœç´¢å…³é”®è¯**: Fulzerasib IBI351 colorectal cancer renal safety

æœªæ‰¾åˆ°ç›¸å…³æ–‡çŒ®ã€‚
```

### Tool Call 8: `search_pubmed`
**Timestamp:** 2026-01-20 20:25:27

**Parameters:**
```json
{
  "query": "ATM mutation colorectal cancer PARP inhibitor efficacy"
}
```

**Result:**
```
**PubMed æœç´¢ç»“æœ**

**æœç´¢å…³é”®è¯**: ATM mutation colorectal cancer PARP inhibitor efficacy
**æ‰¾åˆ°æ–‡çŒ®**: 5 ç¯‡

---

### 1. Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study.

- **PMID**: 37852034
- **ä½œè€…**: Joris S, Denys H, Collignon J
- **æœŸåˆŠ**: ESMO open (2023)
- **æ‘˜è¦**: The Belgian Precision initiative aims to maximize the implementation of tumor-agnostic next-generation sequencing in patients with advanced cancer and enhance access to molecularly guided treatment options. Academic tumor-agnostic basket phase II studies are part of this initiative. The current investigator-driven trial aimed to investigate the efficacy of olaparib in advanced cancers with a (likely) pathogenic mutation (germline or somatic) in a gene that plays a role in homologous recombinatio
- **é“¾æ¥**: https://pubmed.ncbi.nlm.nih.gov/37852034/

---

### 2. Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.

- **PMID**: 33407715
- **ä½œè€…**: Vitiello PP, Martini G, Mele L
- **æœŸåˆŠ**: Journal of experimental & clinical cancer research : CR (2021)
- **æ‘˜è¦**: Despite the advancements in new therapies for colorectal cancer (CRC), chemotherapy still constitutes the mainstay of the medical treatment. For this reason, new strategies to increase the efficacy of chemotherapy are desirable. Poly-ADP-Ribose Polymerase inhibitors (PARPi) have shown to increase the activity of DNA damaging chemotherapeutics used in the treatment of CRC, however previous clinical trials failed to validate these results and pointed out dose-limiting toxicities that hamper the us
- **é“¾æ¥**: https://pubmed.ncbi.nlm.nih.gov/33407715/

---

### 3. Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors.

- **PMID**: 35785170
- **ä½œè€…**: Mekonnen N, Yang H, Shin YK
- **æœŸåˆŠ**: Frontiers in oncology (2022)
- **æ‘˜è¦**: Homologous recombination (HR) is a highly conserved DNA repair mechanism that protects cells from exogenous and endogenous DNA damage. Breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) play an important role in the HR repair pathway by interacting with other DNA repair proteins such as Fanconi anemia (FA) proteins, ATM, RAD51, PALB2, MRE11A, RAD50, and NBN. These pathways are frequently aberrant in cancer, leading to the accumulation of DNA damage and genomic instability known as homologous re
- **é“¾æ¥**: https://pubmed.ncbi.nlm.nih.gov/35785170/

---

### 4. Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol.

- **PMID**: 41099623
- **ä½œè€…**: Spiekman IAC, Mehra N, Zeverijn LJ
- **æœŸåˆŠ**: International journal of cancer (2026)
- **æ‘˜è¦**: BRCA1/2 are crucial in the homologous recombination repair (HRR) pathway, with loss-of-function (LoF) alterations predicting sensitivity to PARP-inhibitors (PARPi). Whether other HRR-gene alterations confer PARPi sensitivity remains unclear. In the Drug Rediscovery Protocol, patients receive off-label drugs matched to their tumor molecular profile. Here, olaparib efficacy and safety were evaluated in adult patients with treatment-refractory, progressive malignancies harboring LoF alterations in 
- **é“¾æ¥**: https://pubmed.ncbi.nlm.nih.gov/41099623/

---

### 5. Off-label use of olaparib in uncommon tumor locations in patients with impaired homologous recombination genes.

- **PMID**: 40155245
- **ä½œè€…**: GarcÃ­a-DÃ­az HC, Larrosa-Garcia M, GÃ³mez-Alonso J
- **æœŸåˆŠ**: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria (2025)
- **æ‘˜è¦**: To describe the effectiveness and safety of olaparib off-label indications in patients with impaired homologous recombination genes and solid tumors different than those authorized.
- **é“¾æ¥**: https://pubmed.ncbi.nlm.nih.gov/40155245/

---

```


---

## References

<a id="ref-pmid-37870968"></a>**[1]** [PMID: 37870968](https://pubmed.ncbi.nlm.nih.gov/37870968/)

<a id="ref-pmid-37133585"></a>**[2]** [PMID: 37133585](https://pubmed.ncbi.nlm.nih.gov/37133585/)

<a id="ref-pmid-37852034"></a>**[3]** [PMID: 37852034](https://pubmed.ncbi.nlm.nih.gov/37852034/)

<a id="ref-fda-adagrasib label"></a>**[4]** [FDA: Adagrasib Label](https://labels.fda.gov)

<a id="ref-fda-lonsurf label"></a>**[5]** [FDA: Lonsurf Label](https://labels.fda.gov)

<a id="ref-fda-sotorasib label"></a>**[6]** [FDA: Sotorasib Label](https://labels.fda.gov)
